OS5.7 First results of the randomized phase II TAVAREC trial on temozolomide with or without bevacizumab in 1p/19q intact 1st recurrence grade II and III glioma

ABSTRACT: Abstract

Background:

The role of bevacizumab in recurrent grade II and III gliomas has not been established. Similar to glioblastoma, uncontrolled studies have shown promising response rates but controlled studies are not available. We conducted a randomized phase II study, in which we investigated the addition of bevacizumab (BEV) to temozolomide (TMZ) in patients with tumors without 1p/19q co-deletion.

Methods:

Eligible were patients with a locally diagnosed grade II or III glioma without 1p/19q co-deletion, with a first and enhancing recurrence after initial radiotherapy. Prior chemotherapy (either TMZ or PCV regimen) was allowed provided patients were at least 6 months off treatment. Patients were treated with either TMZ day 1-5 200 mg/m2 for twelve cycles (arm A), or

SUBMITTER: Idbaih A 

PROVIDER: S-EPMC5782541 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature